Safety and immunogenicity of SCB-2019, an adjuvanted, recombinant SARS-CoV-2 trimeric S-protein subunit COVID-19 vaccine in healthy 12-17 year-old adolescents https://www.medrxiv.org/content/10.1101/2023.02.22.23286317
CleverLibre Social is an inclusive social instance for open discussion, learning, and community. All cultures welcome. Hate speech and harassment strictly forbidden.